Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 8, 2015, Pages 1408-1414

  Naredo, Esperanza ^a   Valor, Lara ^a   De la Torre, Inmaculada ^a   Montoro, María ^a   Bello, Natalia ^a   Martínez Barrio, Julia ^a   Martínez Estupiñán, Lina ^a   Nieto, Juan Carlos ^a   Ovalles Bonilla, Juan Gabriel ^a   Hernández Flórez, Diana ^a   González, Carlos M ^a   López Longo, Francisco Javier ^a   Monteagudo, Indalecio ^a   Carreño, Luis ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Biologic therapy; Doppler; Rheumatoid arthritis; Synovitis; Ultrasound

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PREDNISONE; TOCILIZUMAB;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL LABORATORY; CLINICAL PRACTICE; DAS28; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DOPPLER FLOWMETRY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; FOOT RADIOGRAPHY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY; SIMPLIFIED DISEASE ACTIVITY INDEX; SYNOVITIS;

EID: 84939508726     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev006     Document Type: Article

References (20)

1. Yoshida K, Sung YK, Kavanaugh A et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014;73:595-9.
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509.
3. Brown AK, Quinn MA, Karim Z et al. Presence of significant synovitis in rheumatoid arthritis patients with diseasemodifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54:3761-73.
4. Saleem B, Brown AK, Keen H et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 2009;60:1915-22.
5. Scire CA, Montecucco C, Codullo V et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 2009; 48:1092-7.
6. Balsa A, de Miguel E, Castillo C, Peiteado D, Martín-Mola E. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology 2010;49:683-90.
7. Naredo E, Valor L, De la Torre I et al. Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed? Arthritis Care Res 2013;65:512-7.
8. Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
9. Foltz V, Gandjbakhch F, Etchepare F et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 2012;64:67-76.
10. Saleem B, Brown AK, Quinn M et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 2012;71: 1316-21.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
12. De La Torre I, Valor L, Nieto JC, Montoro M, Carreño L. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study. Reumatol Clin 2014;10: 101-4.
13. Van der Heijde DM. Assessment of radiographs in longitudinal observational studies. J Rheumatol Suppl 2004;69: 46-7.
14. Naredo E, Rodríguez M, Campos C et al. Validity, reproducibility and responsiveness of a 12-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59:512-22.
15. Wakefield RJ, Balint P, Szkudlarek M et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005;32: 2485-7.
16. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013;381:918-29.
17. Van der Maas A, Kievit W, Van den Bemt BJF et al. Downtitration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71:1849-54.
18. Maneiro JR, Perez-Pampin E, Salgado E, Carmona L, Gomez-Reino JJ. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. Rheumatol Int 2014;34: 1059-63.
19. Van den Broek M, Klarenbeek NB, Dirven L et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
20. Iwamoto T, Ikeda K, Hosokawa J et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res 2014;66: 1576-81.